$CRDF
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
https://t.co/aCfO23iJYQ

#daytrade #daytrading #stocks #stockmarketnews #stockstowatch